
Nextcure (NXTC) Stock Forecast & Price Target
Nextcure (NXTC) Analyst Ratings
Bulls say
NextCure Inc's recent acquisition of global rights to SIM0505 outside Greater China positions the company to potentially receive up to $745 million in upfront and milestone payments, along with tiered royalties that can reach double-digit percentages on net sales. The firm is also enhancing value for its antibody-drug conjugates (ADCs) and demonstrating promising preclinical data with robust anti-tumor activity and a favorable safety profile across multiple solid tumor models. Furthermore, NextCure is advancing its development pipeline with plans to initiate Phase I studies for SIM0505 in the U.S. after its ongoing dose-escalation studies in China.
Bears say
NextCure Inc has seen a significant reduction in its projected enterprise value, revised down to $37.5 million from a previous estimate of $75 million, which raises concerns regarding its financial stability and future growth potential. The company is also facing inherent risks associated with the clinical development of its therapies, which may fail to achieve anticipated results. Additionally, the substantial decrease in the price target, adjusted from $36 to $15, further reflects a negative outlook on the company's ability to deliver on its projected performance.
This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.
Nextcure (NXTC) Analyst Forecast & Price Prediction
Start investing in Nextcure (NXTC)
Order type
Buy in
Order amount
Est. shares
0 shares